Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E9.90 EPS (ttm)6.80 Insider Own0.40% Shs Outstand1.30B Perf Week-0.94%
Market Cap87.31B Forward P/E10.42 EPS next Y6.47 Insider Trans-11.38% Shs Float1.30B Perf Month-8.82%
Income8.96B PEG- EPS next Q1.55 Inst Own80.60% Short Float1.25% Perf Quarter-17.62%
Sales24.69B P/S3.54 EPS this Y-22.80% Inst Trans-0.14% Short Ratio2.24 Perf Half Y-7.47%
Book/sh15.75 P/B4.28 EPS next Y5.09% ROA5.30% Target Price86.57 Perf Year4.37%
Cash/sh18.52 P/C3.64 EPS next 5Y-6.25% ROE15.60% 52W Range63.76 - 89.54 Perf YTD-5.95%
Dividend2.28 P/FCF11.25 EPS past 5Y36.20% ROI19.90% 52W High-24.75% Beta1.16
Dividend %3.38% Quick Ratio2.80 Sales past 5Y21.90% Gross Margin82.10% 52W Low5.68% ATR1.42
Employees10000 Current Ratio2.80 Sales Q/Q-21.80% Oper. Margin50.70% RSI (14)40.77 Volatility1.69% 2.04%
OptionableYes Debt/Eq1.41 EPS Q/Q-43.10% Profit Margin14.00% Rel Volume0.64 Prev Close67.53
ShortableYes LT Debt/Eq1.29 EarningsMay 01 AMC Payout80.30% Avg Volume7.20M Price67.38
Recom2.20 SMA20-0.31% SMA50-6.47% SMA200-12.08% Volume4,601,805 Change-0.22%
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
May-24-18 11:07AM  Will Right to Try Bill Boost Biotech ETFs? ETF Trends
May-23-18 04:01PM  Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6 Business Wire
06:00AM  He helped Gilead score billions from HIV, hepatitis C drugs now he's building a cancer fighter American City Business Journals
May-22-18 06:31AM  3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists Motley Fool
May-18-18 02:44PM  FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs InvestorPlace
10:46AM  EU warns of possible birth defect link to GSK's HIV drug Reuters
May-17-18 04:48PM  The FDA Is Trying To 'Shame' Celgene, Gilead Here's Why It Won't Work Investor's Business Daily
04:13PM  Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list American City Business Journals
10:38AM  Sangamo Therapeutics Stock History Motley Fool
10:02AM  FDA names drugmakers likely blocking access to branded drug samples Reuters
09:15AM  3 High-Yield Stocks With Virtual Monopolies Motley Fool
May-16-18 11:10AM  Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone Investor's Business Daily
May-15-18 10:59AM  U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents Business Wire
08:30AM  Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline Business Wire
May-14-18 01:43PM  Why Trumps drug-price pitch makes no sense MarketWatch
May-11-18 05:30PM  Final Trade: IBB, GILD & more CNBC Videos
04:27PM  You should know the cost of a drug or procedure before it... CNBC Videos
12:01PM  Cramer says it's 'very hard to put a price on' lifesaving drugs CNBC
May-10-18 01:00PM  Gilead May Rebound By 12% Short Term Investopedia
May-09-18 04:30PM  Harish Manwani Joins Gilead Sciences Board of Directors Business Wire
11:20AM  Why Bristol-Myers Squibb Stock Crashed in April Motley Fool
08:12AM  3 Stocks That Turned $10,000 Into $1 Million Motley Fool
May-08-18 05:15PM  What Investors Should Know About Gilead Sciences Incs (NASDAQ:GILD) Financial Strength Simply Wall St.
01:50PM  Why Sangamo Therapeutics Stock Dropped Today Motley Fool
09:00AM  Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16 Business Wire
04:58AM  UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing Reuters
May-07-18 07:30AM  Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space? ACCESSWIRE
07:20AM  The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate Zacks
May-04-18 11:48AM  Top Stock Reports for BP, Gilead, Enterprise Products & Colgate Zacks
08:01AM  5 Value Stocks to Book Gains Using Price-to-Book Ratio Zacks
07:00AM  Is Gilead Sciences Stock Finally a Bargain? Motley Fool
May-03-18 03:56PM  Edited Transcript of GILD earnings conference call or presentation 1-May-18 8:30pm GMT Thomson Reuters StreetEvents
01:58PM  Top 5 Biotech Stocks for 2018 Investopedia
10:23AM  Did Gilead Sciences Make a Big Mistake? Motley Fool
10:21AM  Company News for May 3, 2018 Zacks
07:47AM  Gileads latest quarter keeps Wall Street waiting on a turnaround MarketWatch
06:32AM  5 Reasons You Shouldn't Worry About Gilead Sciences' Ugly Q1 Results Motley Fool
May-02-18 04:34PM  Why Molson Coors, Gilead Sciences, and Yum China Holdings Slumped Today Motley Fool -7.83%
04:22PM  Gilead and Snap slip while Apple and AmerisourceBergen jump Associated Press
03:26PM  Is Gilead's 2018 Hepatitis C Drug Franchise Outlook In Trouble? Investor's Business Daily
10:19AM  Gilead Earnings: More Bad News for Big Biotech Barrons.com
09:33AM  The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S. Zacks
09:29AM  Stocks to Watch: Apple, T-Mobile, Mastercard, Snap, CVS, Mondelez, Xerox, Gilead, Clorox, Allstate, Coors The Wall Street Journal
09:23AM  Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1 Zacks
09:12AM  Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV Zacks
08:23AM  Gilead Sinks Most in Over a Year After Disappointing Earnings Bloomberg
07:41AM  Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings Benzinga
06:01AM  Gilead Sciences' First-Quarter Twist: Weak HIV Sales Motley Fool
May-01-18 07:05PM  Gilead Sciences, Inc. Stock Declined After Earnings Miss InvestorPlace
05:55PM  After-hours buzz: SNAP, AAPL, GILD & more CNBC
05:27PM  Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble Investor's Business Daily
05:17PM  Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20% Zacks
04:56PM  Top Gene-Editing Stocks for Long-Term Investors Motley Fool
04:51PM  Gilead hepatitis C drug sales slump, shares fall 5 pct Reuters
04:22PM  Gilead Tumbles After Revenue, Earnings Per Share Fall Short Bloomberg
04:14PM  Gilead shares fall after earnings miss MarketWatch
04:08PM  Gilead: 1Q Earnings Snapshot Associated Press
04:04PM  Gilead misses bottom line estimates CNBC Videos
04:02PM  Gilead Sciences Announces Second Quarter 2018 Dividend Business Wire
04:01PM  Gilead Sciences Announces First Quarter 2018 Financial Results Business Wire
01:06PM  A Look At The Fair Value Of Gilead Sciences Inc (NASDAQ:GILD) Simply Wall St.
08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and Allergan ACCESSWIRE
07:40AM  Blog Exposure - EMA Scientific Committee Recommended Granting Marketing Authorization to Gilead's Biktarvy(R) for HIV-1 Treatment ACCESSWIRE
06:02AM  Better Buy: Biogen Inc. vs. Gilead Sciences Inc. Motley Fool
Apr-30-18 04:27PM  Gilead strikes partnership with Alphabet's Verily MarketWatch
04:06PM  Gilead To Pay Verily $90 Million To Probe Immune Cells Forbes
04:05PM  Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases Business Wire
10:47AM  Gilead Earnings: When OK Will Be Good Enough Barrons.com
10:11AM  Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks
Apr-29-18 06:32AM  What to Expect With Gilead Sciences Inc.'s Q1 Earnings Results Motley Fool
Apr-28-18 02:03PM  AbbVie's First Quarter: Can We Quit Worrying About Humira Now? Motley Fool
Apr-27-18 03:41PM  HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates? Zacks
08:18AM  3 Things You Need to Know About AbbVie's Monster Q1 Earnings Motley Fool
07:30AM  Gilead's three-drug HIV regimen wins European panel approval Reuters
06:36AM  European CHMP Adopts Positive Opinion for Gileads Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) Business Wire
Apr-26-18 11:56PM  [$$] The Million-Dollar Cancer Treatment: Who Will Pay? The Wall Street Journal
11:00AM  Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings? Zacks
09:03AM  Better Buy: Celgene Corporation vs. Gilead Sciences Motley Fool
08:28AM  How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily
06:00AM  Why Gilead's Stock Bulls Are Wrong Investopedia
Apr-25-18 05:31PM  U.S. court upholds dismissal of $200 mln Merck verdict against Gilead Reuters
03:28PM  U.S. court upholds dismissal of $200 million Merck verdict against Gilead Reuters
Apr-24-18 04:12PM  Your Guide to Investing in Zinc-Finger (ZFN) Gene Editing Motley Fool
11:00AM  Is Bellicum Pharmaceuticals, Inc. a Buy? Motley Fool
09:31AM  This Small Biotech Is Building on a Surprising Success Motley Fool
06:31AM  3 Bargain Stocks You Can Buy Right Now Motley Fool
Apr-23-18 03:54PM  Can Gilead Sciences Incs (NASDAQ:GILD) ROE Continue To Surpass The Industry Average? Simply Wall St.
11:33AM  Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy Zacks
Apr-22-18 07:18AM  Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE) Motley Fool
Apr-21-18 08:42AM  8%+ Dividends From My Favorite Sector Now Forbes
Apr-20-18 09:12AM  The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research Zacks
08:00AM  [$$] Big Buys in Alphabet, Facebook for Hot Hedge-Fund Manager Barrons.com
Apr-19-18 03:43PM  Top Research Reports for IBM, McDonald's & Gilead Zacks
02:01PM  Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug MarketWatch
Apr-18-18 06:00PM  Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company PR Newswire
02:00PM  Why Big Biotech Stocks May Get An Earnings Boost Investopedia
12:33PM  Big Biotech ETF Can Bounce Back ETF Trends
10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks
Apr-17-18 05:00PM  Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018 Business Wire
07:30AM  New Research Coverage Highlights DexCom, Equinix, Fitbit, Gilead Sciences, Humana, and Microsoft Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM